Sorted By:


New Policy Solutions for Innovative Treatment Delivery

PhRMA  |  Press Release

The platform can be viewed online here:

Draft Policy Portal

PhRMA  |  From PhRMA


New White Paper: Recognizing Emerging Value in Oncology Treatments

PhRMA  |  Blog Post

In this white paper, we examine key ways in which oncology therapeutics demonstrate increasing clinical value over time, by added data proving additional value of therapies that initially received accelerated approval, use of therapies earlier in the treatment line and earlier in the disease stage, in added disease indications, in combination with other agents, or by targeting specific biomarkers.

PhRMA Statement on National Governors Association’s Prescription Drug Abuse Reduction Policy Academy

PhRMA  |  Press Release

"The Policy Academy reinforces that addressing the problem of non-medical use of prescription drugs is a shared responsibility and all stakeholders, including healthcare providers, generic and name brand manufacturers, medical associations, law enforcement, faith-based and other community organizations, schools and colleges, parents, pharmacists, and state and local governments – must continue to work together to prevent prescription drug abuse and misuse."

ICER Value Assessment Framework

PhRMA  |  Policy Paper

PhRMA submits a letter to convey their feedback regarding the value framework released by the Institute for Clinical and Economic Review (ICER) on September 8, 2015....

Biopharmaceutical Companies Driving Personalized Medicine

PhRMA  |  Policy Paper

The last five years have been characterized by increased momentum in personalized medicine. As scientific understanding has grown, and tools and technologies have advanced, more personalized medicines are progressing through development and reaching patients. New research sponsored by the Persona...

PhRMA Cures Letter of Support

PhRMA  |  Policy Paper

Scientific, regulatory and payment policy reforms included in H.R. 6 are essential to ensuring medical advances continue to be made and are available to the patients who need them.

Clinical Pathways: Overview of Current Practices and Potential Implications for Patients, Payers, and Providers

PhRMA  |  Report

In response to a greater emphasis on paying for value in healthcare, payers and providers are also beginning to link financial incentives to compliance with pathway recommendations and achievement of improved patient outcomes.

PhRMA Comments to the 2017 National Trade Estimate Report

PhRMA  |  Policy Paper

The attached submission, presented to the Trade Policy Staff Committee of the Executive Office of the President on behalf of PhRMA and its member companies, identifies significant barriers to the export of goods, services and overseas direct investment for for inclusion in the 2017 National Trade Estimate Report (NTE).

Hospitals Receive from Commercial Payers 2.5x What They Paid to Acquire These Medicines

PhRMA  |  Graphic

The analysis of 20 medicines also found the amount hospitals receive from commercial payers is 250 percent what they paid to acquire these medicines.


PhRMA  |  From PhRMA


Working to harness the power of the body’s own immune system

PhRMA  |  Blog Post

America’s biopharmaceutical companies, through innovative research and rapidly expanding scientific knowledge, are working to harness the power of the body’s own immune system.

For a Healthier America: Strategies to Combat Prescription Drug Abuse

PhRMA  |  Policy Paper

Given the growing toll related to the abuse of prescription opioids and heroin, we must collectively redouble our efforts to prevent the misuse, abuse and diversion of prescription medicines. We need a balanced approach that ensures appropriate access and use of prescription medicines by patients...

Joint PhRMA - BIO Letter on IPR

PhRMA  |  Policy Paper

The Biotechnology Industry Organization writes to express their support for changes to H.R. 9, the Innovation Act, and S. 1137, the PATENT Act, to preserve the integrity of the Drug Price Competition and Patent Term Restoration Act (commonly referred to as Hatch-Waxman) and the Biologics Price Co...

Senior Manager of Application Support and Power BI

PhRMA  |  PhRMA Career

We are committed to supporting our family of professionals at PhRMA and strive to create programs that help our team members manage the challenges of balancing a fast-paced career with their own personal goals.

Strengthening Efforts to Combat Prescription Drug Diversion

PhRMA  |  Policy Paper

The impact of drug diversion goes beyond just the cost of the prescription drugs that have been diverted for illicit purposes. Prescription drug diversion not only results in increased costs to the health care system through doctor shopping and other forms of fraud, but it also results in increas...

PhRMA Statement on Comments to CMS Regarding Proposed Part D Rule and RFI Exploring Pass-Through Rebates to Seniors at Point of Sale

PhRMA  |  Press Release

We believe this single policy change could yield lower out-of-pocket costs immediately (upon taking effect) for millions of beneficiaries while also generating multi-billion dollar savings to the federal government over a ten year window.”

Researching Alzheimer’s Medicines: Setbacks and Stepping Stones

PhRMA  |  Policy Paper

Between 1998 and 2012, 101 Alzheimer’s drug development projects were halted or became inactive. In that time three new medicines have been approved to treat the symptoms of Alzheimer’s disease – so-called “failed” projects outnumber approved medicines 34 to 1. Setbacks are an inherent pa...

New Report Reveals Growth Trajectories and Top Policy Factors Affecting Biopharmaceutical Innovation & Growth

PhRMA  |  Press Release

Similarly, Harvard researchers report savings on hospital and skilled nursing facility costs of about $1,200 per newly insured Part D beneficiary in 2007.

Foster the Development and Use of ADFs

PhRMA  |  Policy Paper

The challenge of prescription drug abuse is multifaceted and requires a multi-pronged approach that ensures that patients with legitimate medical needs receive the treatments they need, offers a range of options for prescribers and patients to appropriately treat acute and chronic pain, and foste...

New Study: Policy Environment Has a Significant Impact on Biopharmaceutical Investment

PhRMA  |  Blog Post

At the same time, local executives classified both Canada and Japan’s pricing and reimbursement systems as being particularly stringent, rating the market access environments in both economies more on par with emerging economies than developed ones.

Policy Solutions to Foster Innovation and Access to Personalized Medicines: Delivery

Chartpack  |  From Our Network

Policies must ensure that value assessments are patient-centered and align with the way value emerges and changes over time in order to align with the rapid pace of scientific advances in personalized medicine.

How modernizing FDA regulations can benefit patients, providers and payers

PhRMA  |  Blog Post

To read PhRMA and BIO’s joint principles on communications with health care professionals and payers, go to:

Policy Solutions: Promoting Value-Driven Health Care

PhRMA  |  Report

Promoting value-driven health care is an important policy priority for the pharmaceutical industry today.

PhRMA Positions on Quality and Performance Measurement

PhRMA  |  Codes & Guidelines

PhRMA's positions on quality and performance measurement including measure development, measure use and value-based payment....

You have reviewed the first 50 results out of 1100. Each page contains 25 results. You're on page 2.

prev 1 2 3 4 5 6 next